EWING, NJ--(Marketwire - August 07, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”), a late-stage biopharmaceutical company, announced today that one of its academic development partners has initiated a second human clinical trial of RiVax™ in healthy volunteers. RiVax™ is a recombinant subunit vaccine designed to induce protection against exposure to ricin toxin, a category B biothreat. This new trial is intended to evaluate the safety and immunogenicity of an improved formulation of the vaccine containing an adjuvant that is expected to result in long lasting and high levels of protective antibodies. The new trial is being conducted as part of a program funded by a grant from the Orphan Products Division of the FDA (“Food and Drug Administration”). Dr. Ellen Vitetta, Director of the University of Texas Southwestern Medical Center’s Cancer Immunobiology Center, is the Principal Investigator of the study.
